186 related articles for article (PubMed ID: 31178217)
1. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Chen X; Liang W; Wan N; Zhang L; Yang Y; Jiang J; Zhang T
Oral Oncol; 2019 Jul; 94():80-85. PubMed ID: 31178217
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Jin C; Zheng H; Zhan M; Wen F; Xu T
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):577-584. PubMed ID: 31720816
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
Hong S; Zhang Y; Yu G; Peng P; Peng J; Jia J; Wu X; Huang Y; Yang Y; Lin Q; Xi X; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C; Fang W; Zhang L
J Clin Oncol; 2021 Oct; 39(29):3273-3282. PubMed ID: 34379443
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of patients with metastatic or recurrent nasopharyngeal carcinoma in China.
Tang YK; Xu Z; Ye ZM; Li SR; Zhou Q
Head Neck; 2024 Jan; 46(1):5-14. PubMed ID: 37846175
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
[TBL] [Abstract][Full Text] [Related]
8. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Hong S; Zhang L
Chin J Cancer; 2016 Dec; 35(1):100. PubMed ID: 28007026
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
Tian K; Han J; Wang Z; Chen J
Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
13. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
14. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
MacDonald K; Pondel M; Abraham I
J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
[TBL] [Abstract][Full Text] [Related]
19. Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Yang J; Han J; He J; Duan B; Gou Q; Ai P; Liu L; Li Y; Ren K; Wang F; Yao M; Chen N
Front Oncol; 2020; 10():594756. PubMed ID: 33425747
[TBL] [Abstract][Full Text] [Related]
20. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Jin Y; Shi YX; Cai XY; Xia XY; Cai YC; Cao Y; Zhang WD; Hu WH; Jiang WQ
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1717-25. PubMed ID: 22684794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
